



# **Merseyside Inter Agency Drug Misuse Database**

**April – June 2006**

**Sefton DAT**

**Quarter 1 2006/07**

**Martin Chandler, Esther Shepherd,  
Jim McVeigh, Adam Marr and Paul Duffy**

**DRAFT REPORT**

The final version will be available on the IAD website

[www.cph.org.uk/iad](http://www.cph.org.uk/iad)

Contacts:

Martin Chandler

IAD Manager

Centre for Public Health

Faculty of Health & Applied Social Sciences

Liverpool John Moores University

Castle House

North Street

L3 2AY

Tel: (0151) 231 4531

Email: [m.chandler@ljmu.ac.uk](mailto:m.chandler@ljmu.ac.uk)

Esther Shepherd

IAD Researcher

Tel: (0151) 231 4521

Email: [e.shepherd@ljmu.ac.uk](mailto:e.shepherd@ljmu.ac.uk)

Web: [www.cph.org.uk/iad](http://www.cph.org.uk/iad)

# Contents

	<b>Page</b>
<b>Introduction</b>	<b>1</b>
<b>Arrest Referral</b>	<b>2</b>
Table 1: Individuals assessed within Sefton DAT, by Gender and Age Group	
Table 2: Gender by Age Group, of Individuals within Sefton DAT	
Table 3: Reported Main Drug of Use, of Arrestees within Sefton DAT	
Table 4: Reported Main Drug of Use, by Gender	
Table 5: Reported Main Drug of Use, by Age Group	
<b>Probation</b>	<b>5</b>
Table 6: Probation Clients within Sefton DAT, by Gender and Age Group	
Table 7: Number of Clients reporting Daily or Weekly Drug Use within Sefton DAT, by Drug	
Table 8: Reported Main Drug of Use, by Gender	
<b>Syringe Exchange Services</b>	<b>7</b>
<b>Agency</b>	
Table 9: Individuals within Sefton DAT, by Gender: All Clients	
Table 10: Individuals within Sefton DAT, by Gender: Steroid Users omitted	
Table 11: Individuals within Sefton DAT, by Age Group: All Clients	
Table 12: Individuals within Sefton DAT, by Age Group: Steroid Users omitted	
Table 13: Gender by Age Group: All Clients	
Table 14: Gender by Age Group: Steroid Users omitted	
Table 15: Main Drug of Use for Agency Syringe Exchange Clients within Sefton DAT	
Table 16: Main Drug of Use, by Gender	
Table 17: Main Drug of Use, by Age Group	
<b>Pharmacy</b>	<b>12</b>
Table 18: Individuals within Sefton DAT, by Gender	
Table 19: Individuals within Sefton DAT, by Age Group	
Table 20: Gender by Age Group, of Pharmacy Syringe Exchange Clients within Sefton DAT	
<b>Combined</b>	<b>14</b>
Table 21: Individuals in Syringe Exchange within Sefton DAT, by Gender: All Clients	
Table 22: Individuals in Syringe Exchange within Sefton DAT, by Age Group: All Clients	
Table 23: Total Syringes Provided and Returned within Sefton DAT	

**National Drug Treatment Monitoring System (NDTMS) 15**

Table 24: Individuals within Sefton DAT in contact with Treatment Services, by Gender

Table 25: Individuals within Sefton DAT in contact with Treatment Services, by Age Group

Table 26: Ethnicity of Individuals in contact with Treatment Services within Sefton DAT

Table 27: Individuals within Sefton DAT in contact with Treatment services, by Main Drug of Use

**Connexions 18**

Table 28: Individuals within Sefton DAT, by Gender

Table 29: Individuals within Sefton DAT, by Age

Table 30: Drug/Alcohol problem for Clients within Sefton DAT

**Combined Datasets 19**

Table 31: Total Problem Drug Users reported to the IAD within Sefton DAT, by Gender and Age Group

**Cross Matched Datasets 20**

Fig 1: Crossover between Agency & Pharmacy Syringe Exchange and NDTMS datasets

## Introduction

The Inter Agency Drug Misuse Database (IAD), established by Merseyside Drug (and Alcohol) Action Teams, Merseyside Police and the Public Health Sector (now Centre for Public Health) in 1997, supports the need for local information on drug misuse. In particular the IAD aims to:

- Provide comprehensive reporting of problem drug users' (PDUs) characteristics including a range of demographics and the types of drugs used.
- Reflect levels of service and intervention activity.
- Assist in D(A)ATs' (and other responsible bodies) performance management.
- Facilitate the planning and development of services and interventions for PDUs.
- Identify gaps in service provision and delivery, as well as under-served groups as specified by the National Treatment Agency, the Department of Health and by the Centre for Public Health, through interrogation of available data.
- Highlight changes in levels, demographics and characteristics of drug user populations.
- Report back to both individual D(A)ATs and service providers in the form of audits and quarterly reports as well as responding to ad hoc requests.
- Provide summary reporting on an annual basis.

To enable the above the IAD collects data from as many agencies in contact with drug users as possible and is continually seeking to expand the range and scope of data providers. Data are currently collected from criminal justice services, needle exchange schemes (both pharmacy and agency-based), the National Drug Treatment Monitoring System (NDTMS) and Connexions (young people).

### Data considerations

Analysis of data depends on the provision of attributable information. Each service provider records first and last initials, date of birth and gender, for each individual they record a contact with. The combination of these details provides an identifier (attributor) for each individual (e.g.: HF07/12/1974M). This is a nationally recognised system and allows individuals to be tracked through different service providers and across time whilst retaining an acceptable degree of anonymity. The attributor is essential to avoid double counting of individuals both within and across datasets, as well as enabling us to match across datasets. The D(A)AT referred to is the D(A)AT of contact unless otherwise stated.

**PLEASE NOTE:** The IAD will *only* be reporting attributable data for each dataset. In the past, report deadlines have been missed due to data arriving too late to be cleaned and analysed in time, or more often because the data requires a great deal of cleaning and validation before analysis. These reports are useful only if they can arrive within timelines useful to D(A)ATs (ie: in time for NTA quarterly submissions). For this reason, reports will now be sent out according to a strict timetable, with each quarters report to be sent in the first week of the third month following the close of the reporting period. Any data that is missing or non-attributable will not be included in the report. However, Year-to-Date figures will be provided for the current financial year, and will incorporate updated figures from previous quarters.

The Centre for Public Health will continue to work closely with service providers and D(A)ATs in order to improve both the timeliness and quality of monitoring data provided to the IAD. Many service providers are turning to electronic recording of data and it is hoped this will vastly improve the quality of the data as systems improve.

# ARREST REFERRAL (AR)

Quarter 1 (2006/07)

## Introduction

Lighthouse Project provides data on assessments made at custody suites and courts. The total number of assessments figure is based on one person per location per date; this is to ensure duplicate data are not included. Duplicate records may appear for the same individual twice on the same day. In these circumstances data are aggregated to a single record. The same individual may however, be counted twice within the reporting period.

As of this report, Drug of Use is being analysed and reported based on the number of *reports* of each drug of use, by individuals. This is to more accurately reflect the reporting of poly-drug use.

**Table 1: Individuals assessed within Sefton DAT, by Gender and Age Group**

Q1		
Gender	n	%
Male	60	76.9
Female	18	23.1
Age Group		
Under 18	0	0
18-19	8	10.3
20-24	15	19.2
25-29	14	17.9
30-34	24	30.8
35-39	13	16.7
40-44	2	2.6
45+	2	2.6
<b>Total</b>	<b>78</b>	<b>100</b>

**Table 2: Gender by Age Group, of individuals within Sefton DAT**

	Gender			
	Male		Female	
Age Group	n	%	n	%
Under 18	0	0	0	0
18-19	7	11.7	1	5.6
20-24	14	23.3	1	5.6
25-29	11	18.3	3	16.7
30-34	15	25.0	9	50.0
35-39	10	16.7	3	16.7
40-44	1	1.7	1	5.6
45+	2	3.3	0	0
<b>Total</b>	<b>60</b>	<b>100</b>	<b>18</b>	<b>100</b>

**Table 3: Reported Main Drug of Use, of Arrestees within Sefton DAT**

Q1		
Drug of Use	n	%
Heroin	32	41.0
Cocaine	37	47.4
Crack	21	26.9
Methadone	5	6.4
MDMA	1	1.3
Cannabis	7	9.0
Alcohol	2	2.6
Other/Unknown	1	1.3

Please Note: Totals are not provided as figures are non-cumulative and are based on number of reports of a drug of use either alone or in combination with other drugs. Percentages are the % of individuals that reported that drug.

**Table 4: Reported Main Drug of Use, by Gender**

Drug Of Use	Gender			
	Male		Female	
	n	%	n	%
Heroin	18	30.0	14	77.8
Cocaine	33	55.0	4	22.2
Crack	9	15.0	12	66.7
Methadone	4	6.7	1	5.6
MDMA	1	1.7	0	0
Cannabis	7	11.7	0	0
Alcohol	2	3.3	0	0
Other/Unknown	1	1.7	0	0

Please Note: Figures are non-cumulative and are based on number of *reports* of a drug of use, reported either alone or in combination with other drugs. Percentages are the % of individuals that reported that drug within each Gender group.

**Table 5: Reported Main Drug of Use, by Age Group**

Drug Of Use	Age Group					
	Under 19		19– 25		Over 25	
	n	%	n	%	n	%
Heroin	0	0	1	5.6	31	56.4
Cocaine	5	100	11	61.1	21	38.2
Crack	0	0	1	5.6	20	36.4
Methadone	0	0	0	0	5	9.1
MDMA	0	0	1	5.6	0	0
Cannabis	0	0	6	33.3	1	1.8
Alcohol	0	0	0	0	2	3.6
Other/Unknown	0	0	0	0	1	1.8

Please Note: Figures are non-cumulative and are based on number of *reports* of a drug of use, either alone or in combination with other drugs. Percentages are the % of individuals that reported that drug within each Age Group.

## Probation Quarter 1 (2006/07)

### Introduction

Data is provided by Merseyside Probation Services. Data relates to individuals reported through OASys with a reported substance use problem. Individuals who are on ASROs or similar treatment orders are reported to NDTMS.

**NOTE:** Probation figures are based on DAT of Residence, NOT DAT of contact as with other datasets

**Table 6: Probation Clients within Sefton DAT, by Gender and Age Group**

Q1		
Gender	n	%
Male	329	86.4
Female	52	13.6
Age Group		
Under 18	1	<1
18-19	23	6.0
20-24	94	24.7
25-29	63	16.5
30-34	66	17.3
35-39	62	16.3
40-44	41	10.8
45+	31	8.1
<b>Total</b>	<b>381</b>	<b>100</b>

**Table 7: Number of Clients reporting Daily or Weekly Drug Use within Sefton DAT, by Drug**

Q1		
Drug of Use	Daily	Weekly
Heroin	64	19
Methadone	22	0
Crack	30	28
Cocaine	3	13
Amphetamines	1	3
Ecstasy	0	1
Cannabis	48	38

**Table 8: Reported Main Drug of Use, by Gender**

Drug Of Use	Gender			
	Male		Female	
	n	%	n	%
Amphetamines	3	<1	0	0.0
Benzodiazepines	1	<1	0	0.0
Cannabis	104	31.6	4	7.7
Cocaine	19	5.8	3	5.8
Crack	14	4.3	7	13.5
Ecstasy	0	0.0	0	0.0
Heroin	80	24.3	27	51.9
Methadone	5	1.5	1	1.9
Misused Prescribed	0	0.0	0	0.0
Steroids	0	0.0	0	0.0
Unknown	103	31.3	19.2	0.0
<b>Total</b>	<b>329</b>	<b>100</b>	<b>52</b>	<b>100</b>

# SYRINGE EXCHANGE SERVICES

Quarter 1 (2006/07)

## Introduction

Data are collected directly from syringe exchange providers. Analysis of syringe exchange data allows performance monitoring of harm reduction services at both D(A)AT and service provider level. This also facilitates geographical analysis of both distribution and movement of injecting drug users.

## AGENCY SYRINGE EXCHANGE

Table 9: Individuals within Sefton DAT, by Gender: All Clients

Q1		
New Clients	n	%
Male	39	86.7
Female	6	13.3
<b>Total</b>	<b>45</b>	<b>100</b>
All Clients		
Male	288	88.3
Female	38	11.7
<b>Total</b>	<b>326</b>	<b>100</b>

Table 10: Individuals within Sefton DAT, by Gender: Steroids Users omitted

Q1		
New Clients	n	%
Male	16	72.7
Female	6	27.3
<b>Total</b>	<b>22</b>	<b>100</b>
All Clients		
Male	165	82.1
Female	36	17.9
<b>Total</b>	<b>201</b>	<b>100</b>

**Table 11: Individuals within Sefton DAT, by Age Group: All Clients**

Age Group	Q1			
	New Clients		All Clients	
	n	%	n	%
Under 18	0	0	1	0.3
18-19	2	4.4	5	1.5
20-24	10	22.2	42	12.9
25-29	11	24.4	65	20.0
30-34	8	17.8	50	15.4
35-39	6	13.3	86	26.5
40-44	4	8.9	41	12.6
45+	4	8.9	35	10.8
<b>Total</b>	<b>45</b>	<b>100</b>	<b>325</b>	<b>100</b>

**Table 12: Individuals within Sefton DAT, by Age Group: Steroid Users omitted**

Age Group	Q1			
	New Clients		All Clients	
	n	%	n	%
Under 18	0	0	1	0.5
18-19	0	0	0	0
20-24	1	4.5	9	4.5
25-29	3	13.6	29	14.5
30-34	6	27.3	31	15.5
35-39	6	27.3	70	35.0
40-44	3	13.6	32	16.0
45+	3	13.6	28	14.0
<b>Total</b>	<b>22</b>	<b>100</b>	<b>200</b>	<b>100</b>

**Table 13: Gender by Age Group: All Clients**

Age Group	Gender			
	Male		Female	
	n	%	n	%
Under 18	0	0	1	2.7
18-19	5	1.7	0	0
20-24	39	13.5	3	8.1
25-29	58	20.1	7	18.9
30-34	42	14.6	8	21.6
35-39	76	26.4	10	27.0
40-44	36	12.5	5	13.5
45+	32	11.1	3	8.1
<b>Total</b>	<b>288</b>	<b>100</b>	<b>37</b>	<b>100</b>

**Table 14: Gender by Age Group: Steroid Users omitted**

Age Group	Gender			
	Male		Female	
	n	%	n	%
Under 18	0	0	1	2.9
18-19	0	0	0	0
20-24	6	3.6	3	8.6
25-29	23	13.9	6	17.1
30-34	24	14.5	7	20.0
35-39	60	36.4	10	28.6
40-44	27	16.4	5	14.3
45+	25	15.2	3	8.6
<b>Total</b>	<b>165</b>	<b>100</b>	<b>35</b>	<b>100</b>

**Table 15: Main Drug of Use for Agency Syringe Exchange Clients within Sefton DAT**

Q1		
Drug of Use	n	%
Heroin	158	48.5
Methadone	18	5.5
Cocaine*	5	1.5
Amphetamine	5	1.6
Steroids	125	38.3
Various	4	1.2
Unknown	11	3.4
<b>Total</b>	<b>326</b>	<b>100</b>

\*Including Crack

- Of all Steroid users 23 were new clients (51.1% of new clients)
- Of all Heroin users 20 were new clients (44.4% of new clients)

**Table 16: Main Drug of Use, by Gender**

Drug Of Use	Gender			
	Male		Female	
	n	%	n	%
Heroin	129	44.8	29	76.3
Methadone	14	4.9	4	10.5
Cocaine*	4	1.4	1	2.6
Amphetamine	4	1.4	1	2.6
Steroids	123	42.7	2	5.3
Various	4	1.4	0	0
Unknown	10	3.5	1	2.6
<b>Total</b>	<b>288</b>	<b>100</b>	<b>38</b>	<b>100</b>

\*Including Crack

**Table 17: Main Drug of Use, by Age Group**

Drug Of Use	Age Group					
	Under 19		19 – 25		Over 25	
	n	%	n	%	n	%
Heroin	0	0	9	20.0	149	53.6
Methadone	0	0	0	0	18	6.5
Cocaine	0	0	0	0	2	0.7
Amphetamine	0	0	0	0	5	1.8
Steroids	2	66.7	36	80.0	87	31.3
Crack	0	0	0	0	3	1.1
Various	0	0	0	0	4	1.4
Unknown	1	33.3	0	0	10	3.6
<b>Total</b>	<b>3</b>	<b>100</b>	<b>45</b>	<b>100</b>	<b>278</b>	<b>100</b>

## PHARMACY SYRINGE EXCHANGE

**Table 18: Individuals within Sefton DAT, by Gender**

Q1		
New Clients	n	%
Male	177	84.3
Female	33	15.7
<b>Total</b>	<b>210</b>	<b>100</b>
All Clients		
Male	366	83.6
Female	72	16.4
<b>Total</b>	<b>438</b>	<b>100</b>

**Table 19: Individuals within Sefton DAT, by Age Group**

Age Group	Q1			
	New Clients		All Clients	
	n	%	n	%
Under 18	0	0	2	0.5
18-19	4	1.9	6	1.4
20-24	24	11.4	35	8.0
25-29	34	16.2	69	15.8
30-34	41	19.5	85	19.4
35-39	56	26.7	125	28.5
40-44	35	16.7	77	17.6
45+	16	7.6	39	8.9
<b>Total</b>	<b>210</b>	<b>100</b>	<b>438</b>	<b>100</b>

**Table 20: Gender by Age Group, of Pharmacy Syringe Exchange Clients within Sefton DAT**

Age Group	Gender			
	Male		Female	
	n	%	n	%
Under 18	2	0.5	0	0
18-19	6	1.6	0	0
20-24	31	8.5	4	5.6
25-29	55	15.0	14	19.4
30-34	71	19.4	14	19.4
35-39	107	29.2	18	25.0
40-44	62	16.9	15	20.8
45+	32	8.7	7	9.7
<b>Total</b>	<b>366</b>	<b>100</b>	<b>72</b>	<b>100</b>

## COMBINED PHARMACY AND AGENCY SYRINGE EXCHANGE

Analyses here are based on a combination of the aggregated Agency and Pharmacy-based datasets. Data are aggregated by attributor and DAAT to one person per DAAT area.

**Table 21: Individuals in Syringe Exchange within Sefton DAT, by Gender: All Clients**

Q1		
New Clients	n	%
Male	217	85.1
Female	38	14.9
<b>Total</b>	<b>255</b>	<b>100</b>
All Clients		
Male	619	86.1
Female	100	13.9
<b>Total</b>	<b>719</b>	<b>100</b>

**Table 22: Individuals in Syringe Exchange within Sefton DAT, by Age Group: All Clients**

Age Group	Q1			
	New Clients		All Clients	
	n	%	n	%
Under 18	0	0	3	0.4
18-19	6	2.4	11	1.5
20-24	32	12.5	70	9.7
25-29	45	17.6	128	17.8
30-34	50	19.6	125	17.4
35-39	62	24.3	194	27.0
40-44	40	15.7	116	16.2
45+	20	7.8	71	9.9
<b>Total</b>	<b>255</b>	<b>100</b>	<b>718</b>	<b>100</b>

**Table 23: Total Syringes Provided and Returned within Sefton DAT**

	Q1
Syringes Provided– Agency	10644
Syringes Provided– Pharmacy	24632

# National Drug Treatment Monitoring System (NDTMS)

## Quarter 1 (2006/07)

### Background

The NDTMS is the official method for measuring the extent and nature of structured drug treatment in England and Wales. The system is commissioned by the NTA and is operated through nine regional centres – corresponding to the nine government offices for the regions.

Data here are aggregated to one individual, per quarter, per D(A)AT. Individuals presenting in more than one D(A)AT within the time period will therefore be represented more than once in the original data. The D(A)AT referred to is D(A)AT of treatment.

### New Clients

Figures presented here for "new" clients are calculated using the triage date. Those individuals triaged within the reporting period are taken as new clients for this report. However, it should be noted that these individuals may have been triaged, or in contact with treatment services, before this period.

**Table 24: Individuals within Sefton DAT in contact with Treatment Services, by Gender**

Q1		
New Clients	n	%
Male	128	67.7
Female	61	32.3
<b>Total</b>	<b>189</b>	<b>100</b>
All Clients		
Male	942	68.3
Female	437	31.7
<b>Total</b>	<b>1379</b>	<b>100</b>

**Table 25: Individuals within Sefton DAT in contact with Treatment Services , by Age Group**

Age Group	Q1			
	New Clients		All Clients	
	n	%	n	%
Under 18	18	9.5	51	3.7
18-19	5	2.7	25	1.8
20-24	18	9.5	96	7.0
25-29	25	13.2	153	11.1
30-34	42	22.2	283	20.5
35-39	43	22.8	397	28.8
40-44	27	14.3	242	17.6
45+	11	5.8	132	9.6
<b>Total</b>	<b>189</b>	<b>100</b>	<b>1379</b>	<b>100</b>

**Table 26: Ethnicity of Individuals in contact with Treatment Services within Sefton DAT.**

Ethnicity	Q1			
	New Clients		All Clients	
	n	%	n	%
White British	187	98.9	1352	98.0
White Irish	0	0	6	0.4
Other White	0	0	3	0.2
White & Black African	0	0	1	0.1
White & Asian	0	0	1	0.1
Other Mixed	0	0	3	0.2
Other	1	0.5	11	0.8
Unknown	1	0.5	2	0.2
<b>Total</b>	<b>189</b>	<b>100</b>	<b>1379</b>	<b>100</b>

**Table 27: Individuals within Sefton DAT in contact with Treatment Services, by Main Drug of Use**

Drug of Use	Q1			
	New Clients		All Clients	
	n	%	n	%
Heroin	107	56.6	942	68.3
Methadone	6	3.2	55	4.0
Other opiates	2	1.1	10	0.7
Benzodiazepines	0	0	4	0.3
Amphetamines	5	2.7	22	1.6
Cocaine	23	12.2	113	8.2
Crack	6	3.2	26	1.9
Ecstasy	1	0.5	3	0.2
Cannabis	28	14.8	89	6.5
Solvents	0	0	2	0.2
Anti-Depressants	1	0.5	1	0.1
Unknown	10	5.3	112	8.1
<b>Total</b>	<b>189</b>	<b>100</b>	<b>1379</b>	<b>100</b>

## CONNEXIONS

Quarter 1 (2006/07)

### Background

Connexions provide a support service for young people aged 13-19. The Greater Merseyside Connexions Partnership provides data presented here.

**Table 28: Individuals within Sefton DAT, by Gender**

Q1		
Gender	n	%
Male	25	78.1
Female	7	21.9
<b>Total</b>	<b>32</b>	<b>100</b>

**Table 29: Individuals within Sefton DAT, by Age**

Q1		
Age Group	n	%
16	11	34.4
17	5	15.6
18	11	34.4
19	5	15.6
<b>Total</b>	<b>32</b>	<b>100</b>

**Table 30: Drug/Alcohol problem for Clients within Sefton DAT**

Q1		
Substance	n	%
Alcohol/Other*	5	15.6
Drugs	27	84.4
<b>Total</b>	<b>32</b>	<b>100</b>

\*"Other" is generally used to refer to solvents although this is not necessarily always the case.

## COMBINED DATASETS

Quarter 1 (2006/07)

### Introduction

Data presented here are drawn from a combination of datasets relating to Arrest Referrals, Syringe Exchange (Agency and Pharmacy), NDTMS and Connexions. The combined data are aggregated on attributor and D(A)AT area of intervention to produce overall figures for numbers of individuals in contact with services reporting to the IAD. Figures presented here will therefore not necessarily reflect the combined totals of data presented earlier as duplicate attributors are removed. These figures should not be taken as a measure of prevalence of problem drug users, but reflects the total number of problem drug users in contact with a range of agencies. Further information on the processes of data manipulation, aggregation and analysis is available from the IAD Manager.

Probation data was not available in time to be included in the Combined Datasets analysis.

**Table 31: Total Drug Users reported to the IAD within Sefton DAT, by Gender and Age Group**

Q1		
Gender	n	%
Male	1478	74.2
Female	513	25.8
Age Group		
Under 18	82	4.1
18-19	60	3.0
20-24	219	11.0
25-29	329	16.5
30-34	424	21.3
35-39	485	24.4
40-44	247	12.4
45+	145	7.3
<b>Total</b>	<b>1991</b>	<b>100</b>

## CROSS-MATCHED DATASETS

Datasets for 2006/07 from Agency and Pharmacy based Syringe Exchange were cross-matched to each other and to the NDTMS dataset. There exists a small crossover in each D(A)AT area between Agency and Pharmacy Syringe Exchange, with a number of clients accessing both types of service. There is a further crossover between each of the Syringe Exchange types and NDTMS. A small group also exists in each D(A)AT area, of individuals who are accessing all three service types. The diagram below therefore reflects the numbers of individuals attending Syringe Exchange who are also in treatment, or are in both types of Syringe Exchange.

**NB: Numbers in brackets refer to the total reported for that service type. These include the numbers appearing on the crossover sections. Analyses for the crossover areas are based on D(A)AT of Syringe Exchange site. The crossover between Agency and Pharmacy Syringe Exchange is based on the D(A)AT of Agency as this is the more robust dataset.**

**Fig 1: Crossover between Agency & Pharmacy Syringe Exchange and NDTMS datasets**

